# Stimuli-responsive nanoplatforms for precision activation of the STING pathway in cancer immunotherapy

## TL;DR

This paper explores nanotechnology-based platforms that precisely activate the STING pathway in tumors to boost cancer immunotherapy while avoiding harmful side effects.

## Contribution

The paper introduces stimuli-responsive nanoplatforms that enable precise and controllable STING pathway activation in cancer therapy.

## Key findings

- Stimuli-responsive nanoplatforms can activate the STING pathway specifically in tumors, reducing off-target toxicity.
- These nanoplatforms can be combined with other therapies like chemotherapy and photodynamic therapy for enhanced antitumor effects.
- The platforms utilize signals from the tumor microenvironment and external stimuli to trigger STING activation.

## Abstract

The stimulator of interferon genes (STING) pathway plays a unique role in antitumor immunity, bridging innate and adaptive immune responses to initiate a sustained and highly effective antitumor immune response. However, due to the widespread expression of the STING pathway and the lack of clearly distinguishable physiological and pathological features, its excessive or systemic activation can trigger severe adverse effects, such as cytokine storms, thereby limiting its clinical applicability. With the development of nanotechnology, stimuli-responsive nanoplatforms designed based on tumor microenvironment (TME) signals (such as pH, glutathione, reactive oxygen species, hypoxia, and enzymes) and exogenous stimuli (including light, ultrasound, radiation, and magnetic fields) provide a promising strategy for the precise activation of the STING pathway. These nanoplatforms can achieve tumor-specific and controllable STING activation, thereby minimizing off-target toxicity, and can be combined with chemotherapy, radiotherapy, or photodynamic therapy to produce multimodal synergistic antitumor effects. Here, we provide a systematic overview of stimuli-responsive nanoplatforms for STING activation, highlighting their design strategies and how they can reverse immunosuppressive TME through STING pathway activation. Additionally, we discuss the challenges facing their clinical translation and outline future directions, aiming to provide a foundation for further research in this field. In conclusion, stimuli-responsive STING-activating nanoplatforms demonstrate significant potential in antitumor therapy and may serve as a novel therapeutic strategy.

Circular infographic illustrating a synergistic platform for tumor therapy. The left half depicts radiation therapy, chemotherapy, and photodynamic therapy with images of equipment, syringe, and cells. The right half shows response platforms including pH, glutathione, enzyme, reactive oxygen species (ROS), and environmental signals, with nanotechnology elements like light, ultrasound, radiation, and magnetic fields. Central section emphasizes the “Sting” response element.